France
Sensorion is a clinical-stage biotechnology company founded in 2009, with a mission to find solutions for hearing disorders. The company's clinical-stage portfolio includes SENS-401 (Arazasetron), a Phase 2 product being studied in Cisplatin-Induced Ototoxicity (CIO) and in patients scheduled for cochlear implantation in collaboration with Cochlear Limited.
Sensorion has also formed a strategic partnership with Institut Pasteur focused on the genetics of hearing and has two gene therapy programs, OTOF-GT and GJB2-GT, targeting hereditary monogenic forms of deafness. These programs aim to address important hearing loss segments in adults and children.
The latest investment of €50.50M in Post-IPO Equity was secured on February 9, 2024, with participation from Sofinnova Partners, Invus, Redmile Group, and Aquilo Capital Management. Headquartered in France, Sensorion is advancing innovative therapies to restore, treat, and prevent hearing loss disorders within the healthcare and biopharma industries.
